Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
I
424870
vs
K
KOSPI 200
Over the past 12 months, ImmuneOncia Therapeutics Inc has underperformed KOSPI 200, delivering a return of -48% compared to KOSPI 200's +106% growth.
Stocks Performance
424870 vs KOSPI 200
Performance Gap
424870 vs KOSPI 200
Performance By Year
424870 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ImmuneOncia Therapeutics Inc
Glance View
ImmuneOncia Therapeutics is a biopharmaceutical company focused on developing antibody-based cancer treatments, especially drugs that help the immune system attack tumors. Its work centers on early-stage research, preclinical testing, and clinical development of medicines for difficult-to-treat cancers and related immune diseases. The company does not sell a broad consumer product line. It makes money through drug development programs, including partnerships, licensing, and potential future sales or royalties if its candidates reach the market. Its customers are mainly large pharmaceutical partners, research collaborators, and, eventually, hospitals and patients if its medicines are approved. What makes its business different is that it sits near the front of the drug value chain: it creates and advances new therapeutic candidates rather than manufacturing a finished medicine at scale. That means its value depends heavily on scientific results, trial data, and deal-making with bigger drug companies that can help fund development and commercialization.